AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00825071
Drug: Ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4 mg, intravenously
Trial: NCT04438655
Drug: Parenteral prophylaxis
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin - Clavulanic Acid 2000/200 mg at induction of anesthesia, redosing with prolonged surgery.~in case of allergy to penicillin: Clindamycin 600 mg + Gentamycin 2 mg/kg.
Trial: NCT00998101
Drug: cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 400 mg/m2 Cycle 1 day 1 only over 120 minutes 250 mg/m2 Cycle 1 days 8,15 AND on all other cycles days 1,8,15 over 60 minutes
Trial: NCT00998101
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: AUC=6 Day 1 of treatment over 30 minutes every 21 days
Trial: NCT00998101
Drug: ixabepilone
RxNorm normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 mg/m2 , Day 1 over 3 hours every 21 days
Trial: NCT01046318
Drug: OPC-262
RxNorm normalized name: OPC-14523
DrugBank: OPC-14523 (DB05422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPC-262 5 mg will be orally administered once daily fro 52 weeks.
Trial: NCT01157169
Drug: Buprenorphine
RxNorm normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 8 mg Sublingual Tablets
Trial: NCT03016234
Drug: Desflurane
RxNorm normalized name: Desflurane
DrugBank: Desflurane (DB01189)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: On arrival in the operating room, initial intraocular pressure is measured after administration of alcaine 0.5% eye drop and routine monitoring and bispectral index(BIS) are applied. Anesthesia is induced with pentothal sodium inj (thiopental sodium 0.53g) 5-6mg/kg and esmeron inj (rocuronium bromide 50mg/5ml) 1mg/kg. Then endotracheal intubation is performed, anesthesia is maintained with 50% oxygen-air-4\~7% desflurane inhalation and intravenous remifentanil continous infusion (effect site concentration 3-6ng/mL) during operation. Desflurane concentration is titrated to maintain BIS values within a target range 40-60 during operation. Mean arterial blood pressure, peak airway pressure, end tidal carbon dioxide, and IOP on both eyes are measured at defined intervals.
Trial: NCT03016234
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: On arrival in the operating room, initial intraocular pressure is measured after administration of alcaine 0.5% eye drop and routine monitoring and bispectral index(BIS) are applied. Anesthesia is induced with fresofol MCT 1% inj (1% propofol) 1.5-2.5mg/kg and esmeron inj (rocuronium bromide 50mg/5ml) 1mg/kg. Then endotracheal intubation is performed, anesthesia is maintained with intravenous fresofol MCT 2% inj (2% propofol, effect site concentration 2.5-5μg/mL) and remifentanil (effect site concentration 3-6ng/mL) continous infusion. Effect site concentration of propofol is titrated to maintain BIS values within a target range 40-60 during operation. Mean arterial blood pressure, peak airway pressure, end tidal carbon dioxide, and IOP on both eyes are measured at defined intervals.
Trial: NCT02720068
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV infusion
Trial: NCT02720068
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV infusion
Trial: NCT02720068
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral
Trial: NCT00181298
Drug: Memantine
RxNorm normalized name: Memantine
DrugBank: Memantine (DB01043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dispensing initially 5 mg. Dose Increased by 5 mg weekly to 20 mg/d final dose by week 4.
Trial: NCT00839163
Drug: Xarelto (Rivaroxaban, BAY59-7939)
RxNorm normalized name: Xarelto
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10 mg bid main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84).
Trial: NCT00839163
Drug: Xarelto (Rivaroxaban, BAY59-7939)
RxNorm normalized name: Xarelto
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 20 mg bid main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84).
Trial: NCT00839163
Drug: Xarelto (Rivaroxaban, BAY59-7939)
RxNorm normalized name: Xarelto
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 30 mg bid main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84).
Trial: NCT00839163
Drug: Xarelto (Rivaroxaban, BAY59-7939)
RxNorm normalized name: Xarelto
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 40 mg od main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84).
Trial: NCT00839163
Drug: Enoxaparin/Vitamin K-Antagonist
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin/Vitamin K-Antagonist main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84). Enoxaparin was to be administered 1mg/kg bid sc for about 5-7 days. It was to be discontinued when INR was within the therapeutic range 2-3 for 2 consecutive days
Trial: NCT02574975
Drug: methacholine
RxNorm normalized name: Methacholine
DrugBank: Methacholine (DB06709)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methacholine,inhaled cumulative dosage 2.5mg
Trial: NCT03638011
Drug: Exparel
RxNorm normalized name: Exparel
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bilateral TAP Blocks with combination of regular Bupivacaine and EXPAREL
Trial: NCT02574975
Drug: adenosine monophosphate
RxNorm normalized name: Adenosine monophosphate
DrugBank: Adenosine phosphate (DB00131)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenosine monophosphate ,inhaled cumulative dosage 40mg
Trial: NCT02574975
Drug: leukotriene D4
RxNorm normalized name: Leukotriene D4
DrugBank: Leukotriene D4 (DB11858)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leukotriene D4,inhaled cumulative dosage 2.4 μg
Trial: NCT02574975
Drug: budesonide /formoterol
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: budesonide 160μg and formoterol 4.5ug,1 inhalation ,twice daily ,for three months in all participants (80 Anticipated)
Trial: NCT05598086
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: local infiltration of TXA or normal saline in the post-operation would
Trial: NCT00652821
Drug: Tramadol/ APAP
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablets 37.5mg /325mg
Trial: NCT00652821
Drug: Ultracet
RxNorm normalized name: Ultracet
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablets, 37.5mg/325mg
Trial: NCT02525172
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02525172
Drug: intravenous immune globulin
RxNorm normalized name: Intravenous immune globulin (human)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02525172
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00003323
Drug: finasteride
RxNorm normalized name: Finasteride
DrugBank: Finasteride (DB01216)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg/d PO
Trial: NCT00003323
Drug: flutamide
RxNorm normalized name: Flutamide
DrugBank: Flutamide (DB00499)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 250 mg PO tid
Trial: NCT03187379
Drug: Exparel
RxNorm normalized name: Exparel
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exparel liposomal bupivacaine - 20cc Exparel® + 60cc Bupivicaine
Trial: NCT03187379
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60cc Bupivacaine
Trial: NCT04600999
Drug: Favipiravir
RxNorm normalized name: favipiravir
DrugBank: Favipiravir (DB12466)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Name: AVIGAN Generic name: Favipiravir Content: T-705a tablets \[200\]
Trial: NCT00368368
Drug: GK Activator (2)
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg po
Trial: NCT03158584
Drug: Intrathecal Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal administration of Morphine in children undergoing major abdominal surgeries
Trial: NCT02574221
Drug: stannous fluoride toothpaste
RxNorm normalized name: stannous fluoride Toothpaste
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.454% stannous fluoride toothpaste
Trial: NCT00003248
Drug: fludarabine phosphate
RxNorm normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00162851
Drug: alemtuzumab
RxNorm normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01691118
Drug: Fimasartan
RxNorm normalized name: Fimasartan
DrugBank: Fimasartan (DB09279)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00002669
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002669
Drug: dacarbazine
RxNorm normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00101361
Drug: Oxandrolone
RxNorm normalized name: Oxandrolone
DrugBank: Oxandrolone (DB00621)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive oxandrolone (10mg BID) until full healing occurs or for 24 weeks, which ever comes first.
Trial: NCT04066621
Drug: Ceftriaxone Sodium and Sulbactam Sodium for Injection
RxNorm normalized name: Sulbactam Sodium
DrugBank: Ceftriaxone (DB01212)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: daily dose was 75 mg/kg by weight, 1-2 times ivgtt per day, 4 to 14 days
Trial: NCT00680732
Drug: Chloroquine (CQ)
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets 100 mg of chloroquine base
Trial: NCT00680732
Drug: Sulphadoxyne-pyrimethamine (SP)
RxNorm normalized name: Pyrimethamine
DrugBank: Pyrimethamine (DB00205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets
Trial: NCT00841724
Drug: Fludarabine, Busulfan, Thymoglobuline
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00190463
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03023748
Drug: Intravenous Paricalcitol
RxNorm normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twenty four months of intravenous paricalcitol will be given twice or thrice weekly post-hemodialysis depending on frequency of hemodialysis of the patients
Trial: NCT03369847
Drug: budesonide, beclomethasone
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The inhaled corticosteroids we are using for this study are budesonide nebulized solution and beclomethasone metered-dose inhaler. Low-doses for these medications are 0.5mg/day for budesonide and 160 mcg/day for beclomethasone. Patients under 5 years of age will receive low dose budesonide solution 0.25mg/respule to be given twice a day via nebulizer. Budesonide is FDA approved for children under 5 years of age. Patients 5 years and older will receive one beclomethasone metered-dose inhaler (MDI) 40mcg/puff two puffs twice a day via spacer. Beclomethasone is FDA approved for children 5 years and older.
Trial: NCT00251797
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan: 300 to 350 mg/m2 mixing with 250 cc. Dextrose injection. IV infusion over 90 minutes D1 and repeat every 21 days
Trial: NCT00251797
Drug: Thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Thalidomide 50 mg capsule starting from 4 tablets per day Oral D 3 to D 19 of each cycle
Trial: NCT00131443
Drug: Topiramate
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04024696
Drug: Abexinostat
RxNorm normalized name: Abexinostat
DrugBank: Abexinostat (DB12565)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abexinostat Tosylate Tablets
Trial: NCT01079715
Drug: Propranolol
RxNorm normalized name: Propranolol
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosage of 0.5mg/Kg oral, every 6 hours. The study will be discontinued immediately in the presence of serious adverse effects attributable to the pharmacological actions of propranolol (severe hypotension, bradycardia or bronchospasm).~In case such events occur in any of the 3 groups of gestational age, the study could start again with half dose (0.25mg/Kg oral, every 6 hours) after notification to the Ethics Committee.~In case of surgery or induction of anesthesia during the administration of propranolol, the drug should be discontinued at least 24 hours before surgery.~In cases of severe hypotension or bradycardia may be administered one or more of the following drugs:~* Atropine.~* Isoproterenol hydrochloride (isoprenaline.~* Terlipressin.~* Glucagon In case of severe bronchospasm may be used salbutamol aerosol or salbutamol + ipratropium bromide. Betamethasone could be used for aerosol or systemic (intravenous or intramuscular).
Trial: NCT04006769
Drug: Entacapone
RxNorm normalized name: Entacapone
DrugBank: Entacapone (DB00494)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Entacapone tablet
Trial: NCT04006769
Drug: Imatinib Mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imatinib Mesylate tablet
Trial: NCT01923064
Drug: Lipiodol
RxNorm normalized name: Lipiodol
DrugBank: Ethiodized oil (DB00965)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: endoscopic injection of lipiodol + cyanoacrylate + lipiodol for gastric varices
Trial: NCT03669133
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E 800 IU/daily
Trial: NCT00602407
Drug: Cilostazol
RxNorm normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00987415
Drug: allopurinol
RxNorm normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Allopurinol 300 mg daily for one week, then 600 mg daily to complete 24 weeks.
Trial: NCT00987415
Drug: sugar pill
RxNorm normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo 300 mg daily for one week, then 600 mg daily to complete 24 weeks.
Trial: NCT00167479
Drug: risperidone (Risperdal)
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01315574
Drug: Travoprost
RxNorm normalized name: Travoprost
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: One drop Travatan Z (0.004% ophthalmic solution) in affected eye once daily.
Trial: NCT01315574
Drug: Latanoprost
RxNorm normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: One drop Xalatan (0.005% ophthalmic solution) in affected eye once daily.
Trial: NCT01627145
Drug: Solifenacin
RxNorm normalized name: Solifenacin
DrugBank: Solifenacin (DB01591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Solifenacin 5 mg qd,
Trial: NCT03898934
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: receive 6000iu daily for 8 weeks
Trial: NCT01926587
Drug: oral rigosertib
RxNorm normalized name: Rigosertib
DrugBank: Rigosertib (DB12146)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rigosertib will be administered twice a day in fasting conditions for weeks 1, 2, and 3 of a 4-week cycle.
Trial: NCT01926587
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Starting on Day 1 of second week (Day 8) of the cycle, azacitidine will be administered by subcutaneous injection or intravenous infusion at the labeled daily dose of 75 mg/m2, for 7 days.
Trial: NCT05839561
Drug: Letrozole as monotherapy
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole 5 mg daily orally for 10 days from day 0
Trial: NCT01400828
Drug: Bilastine
RxNorm normalized name: bilastine
DrugBank: Bilastine (DB11591)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: 20 mg (encapsulated) tablets QD/14 days
Trial: NCT01400828
Drug: Desloratadine
RxNorm normalized name: Desloratadine
DrugBank: Desloratadine (DB00967)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg (encapsulated) tablets QD/14 days
Trial: NCT00877370
Drug: ertapenem
RxNorm normalized name: Ertapenem
DrugBank: Ertapenem (DB00303)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: One gram ertapenem will be infused intravenously in subjects receiving continuous hemodialysis (CVVHD). Pharmacokinetic sampling in this study will occur with the first dose of ertapenem. While on CVVHD, enrolled subjects will receive ertapenem 1 g intravenously administered over 30 minutes. Two blood samples (5 mL each) will be collected from the arterial (pre-diafilter) port of the CVVHD tubing at time 0 (baseline), ½ hour (end of infusion), 1, 1½, 2, 3, 6, 12, and 24 hours. Effluent (5 mL) will also be collected at these predefined time points from the effluent port of the CVVHD tubing. If ertapenem is discontinued after the first dose then additional samples will be collected at 36 and 48 hours, otherwise ertapenem will be administered as soon as the 24 hour sample is obtained.
Trial: NCT02424149
Drug: Phenazopyridine
RxNorm normalized name: Phenazopyridine
DrugBank: Phenazopyridine (DB01438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01050777
Drug: Liposomal meglumine antimoniate (Glucantime)
RxNorm normalized name: meglumine antimoniate
DrugBank: Meglumine (DB09415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liposomes containing meglumine antimoniate
Trial: NCT01050777
Drug: Liposomal meglumine antimoniate
RxNorm normalized name: meglumine antimoniate
DrugBank: Meglumine (DB09415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liposomal form of meglumine antimoniate
Trial: NCT02277886
Drug: sodium alginate
RxNorm normalized name: Sodium Alginate
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral suspension, 50mg/ml, 20ml once at bed time
Trial: NCT02277886
Drug: esomeprazole
RxNorm normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40mg/tablet, one tablet once before breakfast
Trial: NCT03769311
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Monoclonal antibody against epidermal growth factor receptor (EGFR)
Trial: NCT01939366
Drug: Cebranopadol 100 µg
RxNorm normalized name: Cebranopadol
DrugBank: Cebranopadol (DB12830)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants randomized to 100 μg cebranopadol will start with 100 μg per day and will remain on 100 µg per day.
Trial: NCT02333838
Drug: IV Thiotepa
RxNorm normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV Thiotepa (5 mg/Kg/day for 2 days) (Day -7 and -6) or IV Thiotepa (5 mg/Kg/day for 2 days) (Day -6)
Trial: NCT02333838
Drug: IV Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV fludarabine (40 mg/m²/day for 4 days) (from Day-5 to day -2)
Trial: NCT02333838
Drug: IV Busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: (Busilvex 130 mg/m2/day for 3 days) (Day-5, -4 and -3) or (Busilvex 100 mg/m2/day for 3 days) (Day-5, -4 and -3)
Trial: NCT02333838
Drug: IV Anti-thymocyte globuline
RxNorm normalized name: ANTI-THYMOCYTE GLOBULIN
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (Thymogobuline®, 2.5 mg/kg/day for 2 days) (Day-3 and -2)
Trial: NCT00577590
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin is taken alone
Trial: NCT00577590
Drug: Rosiglitazone
RxNorm normalized name: Rosiglitazone
DrugBank: Rosiglitazone (DB00412)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rosiglitizone is taken with Metformin
Trial: NCT00577590
Drug: Lovaza
RxNorm normalized name: Lovaza
DrugBank: Omega-3-acid ethyl esters (DB09539)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovaza is taken with Metformin
Trial: NCT02712502
Drug: Levofloxacin
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Levofloxacin (Levolet) 750 mg (500 mg Levolet P + P Levolet 250 mg) 1 times a day. The course of treatment is 5 days.~* Decongestants: xylometazoline 2 doses in each nostril two times daily - the first 5 days, then if necessary.
Trial: NCT02712502
Drug: Amoxicillin-Potassium Clavulanate Combination
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin-Potassium Clavulanate Combination (875 mg of amoxicillin trihydrate, potassium clavulanate salt + 125 mg), 2 times a day. The course of treatment 10 days.~• Decongestants: xylometazoline 2 doses in each nostril two times daily - the first 5 days, then if necessary.